STOCK TITAN

Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index

Liquidia (Nasdaq:LQDA) announced its inclusion in the S&P SmallCap 600 Index, effective before market open on June 22, 2026.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Liquidia (Nasdaq:LQDA) announced its inclusion in the S&P SmallCap 600 Index, effective before market open on June 22, 2026. The index tracks 600 U.S. small-cap companies chosen by S&P Dow Jones Indices using market cap, liquidity, public float, and profitability criteria.

Loading...
Loading translation...

Positive

  • Inclusion in the S&P SmallCap 600 Index effective June 22, 2026
  • Meets S&P criteria for market cap, liquidity, float, and profitability

Negative

  • None.
Argus Jun 8 session
+3.31% close to close Open Argus
Details

News Market Reaction – LQDA

On Jun 8, the day this news came out, LQDA closed 3.31% above the previous close.

Data tracked by StockTitan Argus for the Jun 8 session.

Key Figures

Index constituents: 600 companies Effective date: June 22, 2026 Index launch year: 1994
Index constituents
600 companies
S&P SmallCap 600 composition described in release
Effective date
June 22, 2026
Inclusion in S&P SmallCap 600 effective before market open
Index launch year
1994
Year S&P SmallCap 600 was introduced

Historical Context

5 past events · Latest: May 27
5 events
  1. May 27

    Conference appearance

    24h Move
    +3.2%

    Jefferies healthcare conference fireside chat and webcast availability.

  2. May 11

    Earnings results

    24h Move
    +25.6%

    Strong Q1 2026 results driven by YUTREPIA product sales and profitability.

  3. May 06

    Investor conferences

    24h Move
    +5.0%

    Participation in May investor conferences with management presentations and meetings.

  4. May 04

    Earnings date notice

    24h Move
    +0.9%

    Announcement of Q1 2026 earnings release date and webcast details.

  5. Apr 07

    Investor conferences

    24h Move
    -0.8%

    Planned April investor conferences with one-on-one meetings and webcasted chat.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MORRISVILLE, N.C., June 08, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will be added to the S&P SmallCap 600® Index, effective prior to the opening of trading on June 22, 2026.

Introduced in 1994, the S&P SmallCap 600 is a widely followed benchmark of 600 U.S. small-cap companies selected by S&P Dow Jones Indices based on market capitalization, liquidity, shares available for public trading, and profitability criteria.

Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “Inclusion in the S&P SmallCap 600 is a meaningful marker of how far Liquidia has come, and it is a credit to the entire team. It reflects the discipline and execution behind our progress and the foundation we have built through our commitment to patients, innovation and operational excellence. We are focused on the opportunities ahead as we continue our work to revolutionize care for patients with challenging respiratory and vascular diseases.”

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT® technology. PRINT enabled the development of YUTREPIA® (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding the timing and anticipated impact of the Company’s inclusion in the S&P SmallCap 600 Index, potential enhanced visibility within the investment community, as well as the Company’s strategy, operating priorities and future performance, including statements regarding market capitalization, liquidity, financial viability and long-term value creation, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “will,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the Securities and Exchange Commission, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results may differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

Investors:
Jason Adair
Chief Business Officer
919.328.4350

Media Contact:
media@liquidia.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Liquidia (NASDAQ:LQDA) join the S&P SmallCap 600 Index?

Liquidia will be added to the S&P SmallCap 600 Index before trading opens on June 22, 2026. According to Liquidia, this inclusion follows S&P Dow Jones Indices’ selection based on market capitalization, liquidity, public float, and profitability criteria.

What is the S&P SmallCap 600 Index and why is Liquidia’s inclusion important for LQDA stock?

The S&P SmallCap 600 is a benchmark of 600 U.S. small-cap companies selected using defined criteria. According to Liquidia, joining this index recognizes the company’s progress and could increase visibility among investors who track small-cap benchmarks.

Why was Liquidia (LQDA) selected for the S&P SmallCap 600 Index?

Liquidia was selected based on S&P Dow Jones Indices’ criteria, including market capitalization, liquidity, shares available for public trading, and profitability. According to Liquidia, meeting these standards reflects the company’s operational progress and financial profile within the U.S. small-cap universe.

How does S&P SmallCap 600 Index inclusion reflect Liquidia’s business progress?

Inclusion signals that Liquidia satisfies S&P’s size, liquidity, float, and profitability thresholds for small caps. According to Liquidia, this milestone highlights discipline, execution, and a foundation built around patient focus, innovation, and operational performance in respiratory and vascular disease care.

What did Liquidia’s CEO say about joining the S&P SmallCap 600 Index?

CEO Dr. Roger Jeffs called the inclusion a meaningful marker of Liquidia’s progress and a credit to the team. According to Liquidia, he linked this achievement to disciplined execution and commitment to patients, innovation, and operational excellence in treating challenging respiratory and vascular diseases.

Keep reading